GlassScriptPhysician profile
Kimberly L Applegate
NPI 1326313701
$5,667.03
in general payments reported to CMS, 2019-2025
47 companies · $2,576 in 2025
The $2,576 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $398 · 2023: $1,561 · 2024: $800 · 2025: $2,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,187 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,186.94 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $976.08 | 2022-2025 | Datroway, Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $975.11 | 2022-2025 | Calquence, Datroway, Tagrisso |
| Myriad Genetic Laboratories, INC. | $401.26 | 2022-2025 | Myrisk, Bracanalysis Cdx |
| Gilead Sciences, INC. | $386.27 | 2023-2025 | Trodelvy |
| Organogenesis INC. | $320.17 | 2023 | Puraply |
| Janssen Biotech, INC. | $268.49 | 2022-2025 | Tecvayli, Darzalex, Rybrevant |
| Pfizer INC. | $199.30 | 2021-2025 | |
| Incyte Corporation | $198.99 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $192.16 | 2022-2025 | |
| Immunocore Limited | $179.27 | 2025 | Kimmtrak |
| Novartis Pharmaceuticals Corporation | $177.01 | 2021-2025 | |
| Amgen INC. | $168.57 | 2021-2025 | Imdelltra (Amg757), Kyprolis |
| Dova Pharmaceuticals | $115.78 | 2021 | |
| Abbvie INC. | $111.06 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $91.69 | 2021-2023 | Imbruvica |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $66.24 | 2024-2025 | Amtagvi |
| Pharmacosmos Therapeutics INC. | $60.99 | 2023-2025 | Monoferric |
| Astellas Pharma US INC | $57.07 | 2023-2024 | Xtandi |
| Genentech USA, INC. | $56.10 | 2021-2025 | Venclexta, Tecentriq, Tecentriq Hybreza |
| Takeda Pharmaceuticals U.S.A., INC. | $49.71 | 2023-2025 | Alunbrig, Ninlaro |
| Merck Sharp & Dohme LLC | $40.44 | 2022-2025 | Keytruda |
| Caris Mpi, INC. | $39.03 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $37.56 | 2022 | |
| Seagen INC. | $35.68 | 2023 | Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $31.86 | 2025 | |
| Tersera Therapeutics LLC | $30.36 | 2023 | Zoladex |
| Celltrion USA INC. | $26.28 | 2023 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $25.26 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $25.21 | 2024 | Ultomiris |
| Kyowa Kirin, INC. | $23.43 | 2023 | Poteligeo |
| Genzyme Corporation | $22.75 | 2022 | |
| Exelixis INC. | $20.69 | 2025 | Cabometyx |
| Beigene USA, INC. | $20.38 | 2024 | Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.06 | 2023 | |
| Apellis Pharmaceuticals, INC. | $19.06 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.04 | 2025 | Alymsys |
| Deciphera Pharmaceuticals INC. | $18.88 | 2023 | Qinlock |
| Array Biopharma INC | $17.44 | 2023 | Mektovi, Lorbrena, Braftovi |
| Adc Therapeutics America, INC. | $17.41 | 2025 | |
| Cti Biopharma Corp. | $17.32 | 2023 | Vonjo |
| Sobi, INC | $17.02 | 2022 | |
| Taiho Oncology, INC. | $16.95 | 2022 | |
| Emd Serono, INC. | $16.21 | 2022 | |
| Servier Pharmaceuticals LLC | $15.70 | 2025 | |
| Medtronic, INC. | $14.28 | 2025 | Synchromedii |
| Alnylam Pharmaceuticals INC. | $14.27 | 2025 | Givlaari |
| Puma Biotechnology, INC. | $13.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Applegate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.